Siemens Healthcare will showcase several product offerings at the European Society of Cardiology (ESC 2015) meeting 29 August to 2 September in London.
Highlights include the latest iteration of the company's syngo Dynamics cardiovascular software, with new features like smart reporting and intuitive interoperability to enhance communication and efficiency, Siemens said. Also in the software realm, the company's syngo via package offers efficient 3D and advanced visualization software for multiple applications in several modalities, resulting in potentially less-invasive cardiac procedures, according to Siemens.
In angiography, the real-time stent enhancement functionality of its PURE application and CLEARstent Live software is now available for all new Siemens Artis systems. The package facilitates stent positioning by giving a clear display of undeployed stents in relation to previously deployed stents or cardiac anatomy, saving time and contrast material in the process, Siemens said.
In functional cardiac imaging, IQ*SPECT performs ultrafast cardiac imaging with a general-purpose SPECT camera. IQ*SPECT has a novel collimator design, cardiocentric image acquisition, and advanced reconstruction technology that acquires four-times more counts than conventional methods to produce high quality images regardless of patient age, body shape, or size.
For echocardiography, the Acuson SC2000 ultrasound system, Prime edition, is designed to provide a complete and anatomically precise view of the heart, with solutions for both 2D and 3D transthoracic, transesophageal, and intracardiac echocardiography. Advanced imaging tools such as real-time volume color Doppler and automated valve modeling deliver the reliable information, Siemens said. 3D transesophageal echocardiography advancements in 3D/4D and volume color Doppler enable clinicians to visualize form, function, and flow in a single volume view.
In cardiac MRI, Siemens' inline parametric MyoMaps functionality provides an additional layer of quantitative information on tissue composition to potentially detect and quantify diffuse fibrosis at early stages, and to monitor therapy, improving workflow, the company said.
